Similarly, results of combination therapy trial of capecitabine with lapatinib were significantly better than monotherapy with capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (Geyer et al., 2006; Cetin et al., 2014). Here, ERBB2 is linked to breast cancer.